# A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma

> **NCT00640016** · PHASE2 · TERMINATED · sponsor: **MedImmune LLC** · enrollment: 14 (actual)

## Conditions studied

- Asthma

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** CAT-354 1 mg/kg
- **BIOLOGICAL:** CAT-354 5 mg/kg
- **OTHER:** CAT-354 10 mg/kg

## Key facts

- **NCT ID:** NCT00640016
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The study was terminated prematurely by the sponsor due to slow recruitment.
- **Last updated:** 2017-01-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640016, "A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00640016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*